40 likes | 106 Views
The total prevalent cases of Acromegaly in 2017 was 64,508 in seven major markets. In 2017, the prevalent population of Acromegaly in the United States was found to be 28,671 cases while Japan has around 10,690 prevalent cases. The EU5 countries (i.e. the UK, Spain, Germany, France, and Italy) occupied nearly 38.98% of the patient pool amongst 7MM in 2017.<br><br>The market size of Acromegaly was estimated to be USD 956.96 Million in 2017 in the 7MM, which is expected to increase during the study period 2017-2030.<br><br>Robust pipeline, increase in prevalence, more efficacious mono and combination therapies are some of the key factors expected to drive the Acromegaly market forward in the coming years.<br><br>The key players in the Acromegaly market includes Ionis Pharmaceuticals, Chiasma Pharma, Strongbridge Biopharma, Antisense Therapeutics, Crinetics Pharmaceuticals, Midatech Pharma, Camurus, Ipsen, GlyTech, Inc. and many others.<br><br>For more detailed information on Acromegaly Market, visit: https://www.delveinsight.com/report-store/acromegaly-market<br>
E N D